{"id":"tredaptive","rwe":[],"tags":[],"trials":[],"_chembl":null,"aliases":["Tedaptive"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"_scrapedAt":"2026-03-27T23:39:07.722Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01054508","phase":"PHASE4","title":"Effect of Tredaptive on Serum Lipoproteins and Inflammatory Markers","status":"COMPLETED","sponsor":"Manchester University NHS Foundation Trust","startDate":"2010-06","conditions":"Hypercholesterolemia","enrollment":38},{"nctId":"NCT01683656","phase":"PHASE4","title":"ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART","status":"TERMINATED","sponsor":"Calmy Alexandra","startDate":"2012-08","conditions":"HIV, Atherosclerosis","enrollment":4},{"nctId":"NCT01118598","phase":"PHASE4","title":"Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"Hull University Teaching Hospitals NHS Trust","startDate":"2010-06","conditions":"Polycystic Ovary Syndrome","enrollment":34},{"nctId":"NCT01335997","phase":"PHASE3","title":"Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-05-01","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":1139},{"nctId":"NCT01052311","phase":"PHASE4","title":"The Impact of Tredaptive on Flow-Mediated Dilation in Cardiac Patients","status":"TERMINATED","sponsor":"Sheba Medical Center","startDate":"2010-07","conditions":"Coronary Artery Disease, Dyslipidemia","enrollment":8},{"nctId":"NCT01012219","phase":"PHASE1","title":"A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-11","conditions":"Primary Hypercholesterolemia, Mixed Hyperlipidemia","enrollment":36},{"nctId":"NCT01071278","phase":"","title":"Lipid Management in Clinical Practice (MK-0524A-115)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-10","conditions":"Lipid Metabolism Disorder","enrollment":2390},{"nctId":"NCT01414166","phase":"PHASE3","title":"Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-09","conditions":"Dyslipidemia","enrollment":244},{"nctId":"NCT01228019","phase":"","title":"Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-12","conditions":"Hypercholesterolemia, Mixed Dyslipidemia","enrollment":1166},{"nctId":"NCT02153879","phase":"PHASE4","title":"Characterization of High Density Lipoprotein (HDL) in Type 2 Diabetes (T2D) After Fenofibrate or Niacin Treatment","status":"COMPLETED","sponsor":"Institut Investigacio Sanitaria Pere Virgili","startDate":"2009-02","conditions":"Type 2 Diabetes Mellitus, Dyslipidemia","enrollment":30},{"nctId":"NCT01239992","phase":"PHASE4","title":"Effect of Niacin/Laropiprant on Postprandial Lipoprotein Metabolism in Patients With Dyslipoproteinemia","status":"TERMINATED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2011-06","conditions":"Hyperlipoproteinemia, Metabolic Syndrome","enrollment":12},{"nctId":"NCT00461630","phase":"PHASE3","title":"Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2007-01","conditions":"Cardiovascular Disease, Peripheral Arterial Disease, Diabetes Mellitus","enrollment":25673},{"nctId":"NCT01391377","phase":"NA","title":"Effects of Niacin on Good Cholesterol in People With Peripheral Arterial Disease","status":"TERMINATED","sponsor":"Bayside Health","startDate":"2011-07","conditions":"Peripheral Arterial Disease","enrollment":7},{"nctId":"NCT01450410","phase":"PHASE4","title":"Nicotinic Acid Composition of HDL and Arterial Endothelium Function in Premature Coronary Heart Disease and High HDL","status":"TERMINATED","sponsor":"Xavier Pinto Sala","startDate":"2012-07","conditions":"Dyslipidemias","enrollment":12}],"_emaApprovals":[],"_faersSignals":[{"count":24,"reaction":"MYALGIA"},{"count":19,"reaction":"RASH"},{"count":14,"reaction":"ABDOMINAL DISCOMFORT"},{"count":10,"reaction":"ANGIOEDEMA"},{"count":10,"reaction":"COGNITIVE DISORDER"},{"count":10,"reaction":"CONSTIPATION"},{"count":9,"reaction":"PRURITUS"},{"count":8,"reaction":"DIARRHOEA"},{"count":8,"reaction":"GASTROINTESTINAL DISORDER"},{"count":7,"reaction":"FAECAL INCONTINENCE"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":5,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Tredaptive","genericName":"Tredaptive","companyName":"Sheba Medical Center","companyId":"sheba-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}